Theresa Janke
Gründer bei 4D MOLECULAR THERAPEUTICS, INC.
Aktive Positionen von Theresa Janke
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
4D MOLECULAR THERAPEUTICS, INC. | Personalreferent | 12.09.2013 | - |
Gründer | 12.09.2013 | - | |
Geschäftsführer | 01.04.2018 | 01.02.2020 | |
Public Communications Contact | - | - | |
Corporate Officer/Principal | 01.02.2020 | 01.06.2021 |
Karriereverlauf von Theresa Janke
Ehemalige bekannte Positionen von Theresa Janke
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Ignite Immunotherapy, Inc.
Ignite Immunotherapy, Inc. BiotechnologyHealth Technology Part of Pfizer Inc., Ignite Immunotherapy, Inc. is a company that designs and develops oncolytic virus vaccines. The company is based in New York, NY. The company was founded by David Schaffer, Douglas Hanahan, David H. Kirn, Theresa Janke, Melissa Kotterman. The CEO is Monika A. Vnuk. | Direktor/Vorstandsmitglied | - | 01.10.2019 |
Gründer | - | 01.10.2019 | |
SILLAJEN, INC. | Corporate Officer/Principal | 01.01.2013 | 01.01.2014 |
CELGENE | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2013 | 01.01.2014 |
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2007 | 01.01.2013 |
Ausbildung von Theresa Janke
University of California, Santa Barbara | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Südkorea | 2 |
Operativ
Founder | 2 |
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Sektoral
Health Technology | 5 |
Commercial Services | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
4D MOLECULAR THERAPEUTICS, INC. | Health Technology |
SILLAJEN, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
Ignite Immunotherapy, Inc.
Ignite Immunotherapy, Inc. BiotechnologyHealth Technology Part of Pfizer Inc., Ignite Immunotherapy, Inc. is a company that designs and develops oncolytic virus vaccines. The company is based in New York, NY. The company was founded by David Schaffer, Douglas Hanahan, David H. Kirn, Theresa Janke, Melissa Kotterman. The CEO is Monika A. Vnuk. | Health Technology |
- Börse
- Insiders
- Theresa Janke
- Erfahrung